Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Monopar Therapeutics Inc (MNPR) has issued an announcement.
Monopar Therapeutics Inc. has announced the milestone achievement of successfully administering their uPAR-targeted imaging radiopharmaceutical, MNPR-101-Zr, to the first patient in an open-label Phase 1 clinical trial. This marks a significant step forward in their efforts to advance this innovative diagnostic tool in the medical field.
For a thorough assessment of MNPR stock, go to TipRanks’ Stock Analysis page.